Sanjivani Paranteral Ltd

Book closure and AGM details

• Book closure from 10 September 2026 to 16 September 2026, inclusive, for the 32nd AGM.
• Record date fixed as 9 September 2026 to determine voting eligibility.
• AGM will be held on 16 September 2026 at 11:00 IST.
• E-voting period runs 13 September 2026, 09:00 IST to 15 September 2026, 17:00 IST.
• Security affected: equity shares of Sanjivani Paranteral Limited.
• Electronic voting facility available; remote e-voting window provided.

AGM details

• AGM date and time: 16 September 2026 at 11:00 IST.
• Mode: VC/OAVM; venue deemed at the registered office.
• Register of Members/Transfer Books closed 10–16 September 2026 (inclusive).
• Remote e-voting period: 13–15 September 2026.
• Cut-off date for voting eligibility: 9 September 2026.

Ordinary business resolutions

• Adopt Audited Financial Statements for the year ended 31 March 2026.
• Re-appoint Ashwani Khemka, who retires by rotation.

Voting status

• Voting results not disclosed in notice.

Remuneration and terms

• Remuneration proposed for Ashwani Khemka: Rs 12.5 lakh per month.
• Terms remain as approved by members via postal ballot on 20 June 2024.

Annexure: Director details

• Ashwani Khemka, DIN 00337118, born 31-01-1971.
• Date of first appointment: 05-10-1994.
• Shareholding: 36,32,102 shares.
• Experience: 30+ years.
• Remuneration drawn: Rs 12.5 lakh per month.
• Other directorships: SPL Infusion Private Limited; Genesen Labs Limited.

Standalone financials

• Revenue from operations: ₹6,476.39 Lakhs; down 7.61% YoY.
• Total income: ₹6,600.11 Lakhs (Standalone).
• Profit after tax: ₹692.32 Lakhs.
• Earnings per share (Basic): ₹5.67.
• Dividend: Board did not declare any dividend.
• Net cash flows from operating activities: ₹(155.25) Lakhs.

Consolidated financials

• Revenue from operations (Consolidated): ₹6,866.57 Lakhs.
• Total income (Consolidated): ₹6,975.64 Lakhs.
• Profit after tax (Consolidated): ₹669.39 Lakhs.
• Earnings per share (Basic) (Consolidated): ₹5.49.

Capital structure & liquidity

• Warrants converted: 4,02,606; total 6,00,000 converted.
• Equity share capital after conversion: ₹1,228.43 Lakhs.
• Standalone borrowings: ₹667.16 non-current, ₹94.48 current.
• Consolidated borrowings: ₹856.65 non-current, ₹571.39 current.
• Cash & cash equivalents: Standalone ₹115.00 Lakhs; Consolidated ₹124.32 Lakhs.

Strategic growth engines & partnerships

• SPL Infusion Private Limited is 60.87% owned; growth engine.
• Alevia Healthcare S.R.O. (EU) is associate; ₹72.51 Lakhs investment.
• Geographic expansion into Latin America, Africa, Middle East; registrations advancing.
• Pune IV fluids facility commissioned; strengthens growth engine.
• Francophone Africa approvals converting to market access.
• EU nutraceutical foothold via minority investment in Alevia.

Governance & compliance

• Board changes: Basant Shrivastava appointed Independent Director on 11 Sep 2025.
• Board meetings: eight in FY2025-26.
• Audit: Standalone and Consolidated reports unqualified; no fraud reported.
• Related party transactions: arm's length; no material RPTs.
• CSR: CSR obligation ₹7.24 Lakh; spent ₹7.24; set-off ₹7.94.
• Secretarial audit: no qualifications.

Outlook & risks

• FY27 outlook: growth from base, SPL Infusion, and Alevia; diversified exports.
• Risks: tariffs/change in regulation, FX volatility, and supply-chain disruptions.
• Management focus: expand capacity, registrations, and international partnerships.

Resolutions and outcomes

• Special: Issuance of up to 5 lakh convertible warrants to promoter group on preferential basis; approved.
• Ordinary Resolution: Related party transactions with SPL Infusion Private Limited; approved.
• Material impact: potential dilution from warrants and related party transaction with SPL Infusion Private Limited.

Consolidated financial highlights

• Total Income: ₹239.90 Mn in Q1 FY27; +33.81% YoY.
• EBITDA: ₹43.21 Mn; margin 18.01% (up 305 bps YoY).
• PAT: ₹24.91 Mn; margin 10.38% (up 73 bps YoY).
• EPS: ₹2.03.
• Exports: ₹176.10 Mn, 90.50% of revenue; +33.49% YoY.

Segment performance

• Injectables revenue: ₹110.12 Mn; 56.59% of revenue; +22.54% YoY.
• Tablets revenue: ₹84.28 Mn; 43.32% of revenue.
• Nutraceuticals revenue: ₹0.18 Mn; 0.09% of revenue.

Outlook and strategy

• Focus on strengthening manufacturing capabilities and product portfolio; expand domestic and international presence.

Business Overview

• Mumbai-based pharma with 30+ years in injectables, orals, IV fluids, and nutraceuticals.
• Operates 4 manufacturing facilities across India and Europe; exports to 25 countries.
• JV with Alevia Prague (45% stake); Prague operations started 2025.
• Export-led model; 78.5% of FY26 revenue from exports across 25 countries.
• Multi-vertical platform spanning base business, IV fluids, and nutraceuticals.

Operational Highlights

• Q1 FY27 revenue from operations ₹238.39 Mn; EBITDA ₹43.21 Mn; PAT ₹24.91 Mn.
• IV Fluids: SPL Infusion Pune plant, 60 Mn bottles/year; commercial from Dec 2025.
• Prague JV 45% stake; CY25 revenue EUR 0.5-0.6 Mn; profit share from CY26.
• Export share of revenue in Q1 FY27: 90.50%; exports ₹176.10 Mn.
• Mar 2026 Middle East shipping disruption impacted Q4 exports; rerouting via Saudi Arabia-Turkey restored shipments.

Financial Performance

• FY26 consolidated revenue ₹686.7 Mn; EBITDA ₹114.0 Mn; EBITDA margin 16.3%.
• Q1 FY27 EBITDA ₹43.21 Mn; PAT ₹24.91 Mn; revenue ₹238.39 Mn.
• Export revenue ₹176.10 Mn; export share 90.50% of Q1 FY27 revenue.
• Standalone FY26 D/E 0.28; current ratio 1.38; ROE 13.2%; ROCE 15.6%.
• FY27 revenue guidance across verticals: ₹1,450 Mn total (Base ₹800-850 Mn; IV ₹600-650 Mn).

Strategic Outlook

• Three-engine growth: base exports, IV fluids, and nutraceuticals; FY27 revenue target ₹1,450 Mn.
• Pune IV plant capacity 60 Mn bottles/year; commercial ramp; breakeven expected FY27.
• Promoter stake target 31.3% in 2 years; warrant issue under consideration.
• Prague JV majority stake under negotiation; CY25 revenue not consolidated; profit share from CY26.
• Export footprint: 25 countries; core markets CIS/MEA/LatAm accounted for 78.5% FY26 revenue.

Financial results and annual report

• Unaudited Q1 FY2026 results with Limited Review Report approved; attached as Annexure I.
• Annual Report and Directors' Report for FY2025-26 approved.

AGM notice and shareholding records

• Notice for 32nd AGM scheduled for 16 September 2026 via VC/OAVM.
• Register of Members and share transfer books to remain closed 10–16 September 2026.

Scrutinizer appointment

• HD & Associates, Company Secretaries, appointed Scrutinizer to conduct remote e-voting.

Meeting Details

• Board meeting scheduled for 14 August 2026 at the company's registered office.

Key Agenda Items

• Consider and approve unaudited quarterly results for quarter ended 30 June 2026 with Limited Review Report.
• Consider and approve annual report and Director Report for year ended 31 March 2026.
• Fix date, venue, and time and approve draft notice for 32nd AGM.
• Appoint M/s. HD & Associates as Scrutinizer for remote e-voting at AGM.
• Any other matter with chair's permission and consent of majority including at least one Independent Director.

Other Notes

• Approved results will be communicated after conclusion of the board meeting.